Bone Biologics (BBLG) Assets Average (2013 - 2026)

Bone Biologics (BBLG) has reported Assets Average for 13 consecutive years, with $6.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Assets Average rose 53.23% year-over-year to $6.1 million; the TTM figure through Dec 2025 stood at $6.1 million (up 53.23% YoY), while the FY2025 annual figure was $4.8 million, up 27.09% from the prior year.
• Assets Average declined to $6.1 million in Q4 2025 per BBLG's latest filing, from $6.7 million in the prior quarter.
• Across five years, Assets Average topped out at $7.6 million in Q1 2023 and bottomed at $28415.5 in Q3 2021.
• Historically, Assets Average has averaged $4.7 million across 5 years, with a median of $5.1 million in 2025.
• Annual changes were most pronounced in 2022 — Assets Average jumped 19009.04% — and 2024, when it plunged 51.18%.
• Bone Biologics' Assets Average stood at $3.4 million in 2021, then surged by 103.58% to $6.8 million in 2022, then sank by 36.38% to $4.4 million in 2023, then retreated by 9.03% to $4.0 million in 2024, then soared by 53.23% to $6.1 million in 2025.
• Business Quant data shows BBLG's Assets Average at $6.1 million in Q4 2025, $6.7 million in Q3 2025, and $5.1 million in Q2 2025.